deferoxamine has been researched along with Hyperglycemia in 9 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hyperglycemia: Abnormally high BLOOD GLUCOSE level.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This study examined the role of deferoxamine (DFX) in brain injury and HT in a rat model of transient focal ischemia with hyperglycemia." | 7.75 | Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia. ( Hua, Y; Keep, RF; Xi, G; Xing, Y, 2009) |
| " This study examined the role of deferoxamine (DFX) in brain injury and HT in a rat model of transient focal ischemia with hyperglycemia." | 3.75 | Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia. ( Hua, Y; Keep, RF; Xi, G; Xing, Y, 2009) |
| "To determine whether leukocytosis, hyperglycemia, vomiting, and opacities in abdominal radiographs are indicators of a serum iron concentration of > 300 micrograms/dL in adult iron overdose patients, a retrospective medical record review was undertaken at a university medical center of all patients older than 12 years of age for whom clinical data were collected before deferoxamine therapy and within 6 hours of iron ingestion." | 3.69 | Leukocytosis, hyperglycemia, vomiting, and positive X-rays are not indicators of severity of iron overdose in adults. ( Palatnick, W; Tenenbein, M, 1996) |
| "A hallmark of diabetes mellitus is the breakdown of almost every reparative process in the human body, leading to critical impairments of wound healing." | 1.46 | Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing. ( Dong, Y; Duscher, D; Gurtner, GC; Hu, MS; Januszyk, M; Khong, SM; Longaker, MT; Maan, ZN; Walmsley, GG; Whittam, AJ, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (11.11) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wong, CM | 1 |
| Zhang, Y | 1 |
| Huang, Y | 1 |
| Duscher, D | 1 |
| Januszyk, M | 2 |
| Maan, ZN | 1 |
| Whittam, AJ | 1 |
| Hu, MS | 1 |
| Walmsley, GG | 1 |
| Dong, Y | 1 |
| Khong, SM | 1 |
| Longaker, MT | 1 |
| Gurtner, GC | 2 |
| Xing, Y | 1 |
| Hua, Y | 1 |
| Keep, RF | 1 |
| Xi, G | 1 |
| Thangarajah, H | 1 |
| Yao, D | 1 |
| Chang, EI | 1 |
| Shi, Y | 1 |
| Jazayeri, L | 1 |
| Vial, IN | 1 |
| Galiano, RD | 1 |
| Du, XL | 1 |
| Grogan, R | 1 |
| Galvez, MG | 1 |
| Brownlee, M | 1 |
| Simonse, E | 1 |
| Valk-Swinkels, CG | 1 |
| van 't Veer, NE | 1 |
| Ermens, AA | 1 |
| Veldkamp, EJ | 1 |
| Palatnick, W | 1 |
| Tenenbein, M | 1 |
| Abdel-Wahab, MH | 1 |
| Abd-Allah, AR | 1 |
| El-Khatib, AS | 1 |
| Moustafa, AM | 1 |
| Abdel-Aziz, AA | 1 |
| Al-Shabanah, OA | 1 |
| El-Kashef, HA | 1 |
| James, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers[NCT03137966] | Phase 2 | 174 participants (Anticipated) | Interventional | 2022-12-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 other studies available for deferoxamine and Hyperglycemia
| Article | Year |
|---|---|
Bone morphogenic protein-4-induced oxidant signaling via protein carbonylation for endothelial dysfunction.
Topics: Acetylcholine; Animals; Antihypertensive Agents; Aorta; Apoptosis; Bone Morphogenetic Protein 4; Cel | 2014 |
Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing.
Topics: Age Factors; Amino Acids, Dicarboxylic; Animals; Deferoxamine; Diabetes Mellitus; Hyperglycemia; Iro | 2017 |
Effects of deferoxamine on brain injury after transient focal cerebral ischemia in rats with hyperglycemia.
Topics: Animals; Blood-Brain Barrier; Body Water; Brain; Brain Chemistry; Brain Edema; Deferoxamine; Hemoglo | 2009 |
The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues.
Topics: Animals; Cells, Cultured; Deferoxamine; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus | 2009 |
Iron autointoxication in a 16-year-old girl: a protective role for hepcidin?
Topics: Acidosis; Adolescent; Antimicrobial Cationic Peptides; Deferoxamine; Female; Ferrous Compounds; Hema | 2013 |
Leukocytosis, hyperglycemia, vomiting, and positive X-rays are not indicators of severity of iron overdose in adults.
Topics: Adolescent; Adult; Blood Glucose; Deferoxamine; Drug Overdose; Female; Humans; Hyperglycemia; Iron; | 1996 |
Possible protective effect of melatonin and/or desferrioxamine against streptozotocin-induced hyperglycaemia in mice.
Topics: Animals; Blood Glucose; Deferoxamine; Glutathione; Hyperglycemia; Lipid Peroxidation; Lipids; Male; | 2000 |
Effects of aminoguanidine and desferrioxamine on some vascular and biochemical changes associated with streptozotocin-induced hyperglycaemia in rats.
Topics: Analysis of Variance; Animals; Blood Glucose; Body Weight; Chelating Agents; Deferoxamine; Drug Inte | 2001 |
Acute iron poisoning: assessment of severity and prognosis.
Topics: Child; Deferoxamine; Humans; Hyperglycemia; Iron; Leukocytosis; Poisoning; Prognosis | 1970 |